Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Robert Bradway, chairman and CEO said, “Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong ...

Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday, Feb. 12, 2025. Narimon Honarpour, senior vice president of global ...

Amgen's newer drugs and its pipeline will be key to countering biosimilar versions of older drugs and branded competition. We see Repatha as a $3 billion opportunity despite price pressure ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences is a steady dividend payer with a growing payout. For a while, though, ...

Management emphasized its commitment to driving pipeline development, especially in emerging therapeutic areas like oncology and rare diseases. Updates on MariTide, Amgen's weight-reduction ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...